Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation

Masanobu Fujimoto, Melissa Andrew, Lihong Liao, Dongsheng Zhang, Gozde Yildirim, Patrick Sluss, Bhanu Kalra, Ajay Kumar, Shoshana Yakar, Vivian Hwa, Andrew Dauber

Research output: Contribution to journalArticle

Abstract

Bioactive free IGF-I is critically important for growth. The bioavailability of IGF-I is modulated by the IGF-binding proteins (IGFBPs) and their proteases, such as pregnancy-associated plasma protein-A2 (PAPP-A2). We have created a mouse model with a specific mutation in PAPPA2 identified in a human with PAPP-A2 deficiency. The human mutation was introduced to the mouse genome via a knock-in strategy, creating knock-in mice with detectable protein levels of Papp-a2 but without protease activities. We found that the Pappa2 mutation led to significant reductions in body length (10%), body weight (10% and 20% in males and females, respectively), and relative lean mass in mice. Micro-CT analyses of Pappa2 knock-in femurs from adult mice showed inhibited periosteal bone expansion leading to more slender bones in both male and female mice. Furthermore, in the Pappa2 knock-in mice, insulin resistance correlated with decreased serum free IGF-I and increased intact IGFBP-3 concentrations. Interestingly, mice heterozygous for the knock-in mutation demonstrated a growth rate for body weight and length as well as a biochemical phenotype that was intermediate between wild-type and homozygous mice. This study models a human PAPPA2 mutation in mice. The mouse phenotype closely resembles that of the human patients, and it provides further evidence that the regulation of IGF-I bioavailability by PAPP-A2 is critical for human growth and for glucose and bone metabolism.

Original languageEnglish (US)
Pages (from-to)1363-1376
Number of pages14
JournalEndocrinology
Volume160
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Insulin-Like Growth Factor I
Biological Availability
Glucose
Mutation
Growth
varespladib methyl
Blood Proteins
Peptide Hydrolases
Body Weight
Phenotype
Bone and Bones
Protein Deficiency
Pregnancy
Insulin-Like Growth Factor Binding Proteins
Insulin-Like Growth Factor Binding Protein 3
Bone Development
Femur
Insulin Resistance
Genome

ASJC Scopus subject areas

  • Endocrinology

Cite this

Fujimoto, M., Andrew, M., Liao, L., Zhang, D., Yildirim, G., Sluss, P., ... Dauber, A. (2019). Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation. Endocrinology, 160(6), 1363-1376. https://doi.org/10.1210/en.2018-00755

Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation. / Fujimoto, Masanobu; Andrew, Melissa; Liao, Lihong; Zhang, Dongsheng; Yildirim, Gozde; Sluss, Patrick; Kalra, Bhanu; Kumar, Ajay; Yakar, Shoshana; Hwa, Vivian; Dauber, Andrew.

In: Endocrinology, Vol. 160, No. 6, 01.06.2019, p. 1363-1376.

Research output: Contribution to journalArticle

Fujimoto, M, Andrew, M, Liao, L, Zhang, D, Yildirim, G, Sluss, P, Kalra, B, Kumar, A, Yakar, S, Hwa, V & Dauber, A 2019, 'Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation', Endocrinology, vol. 160, no. 6, pp. 1363-1376. https://doi.org/10.1210/en.2018-00755
Fujimoto, Masanobu ; Andrew, Melissa ; Liao, Lihong ; Zhang, Dongsheng ; Yildirim, Gozde ; Sluss, Patrick ; Kalra, Bhanu ; Kumar, Ajay ; Yakar, Shoshana ; Hwa, Vivian ; Dauber, Andrew. / Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation. In: Endocrinology. 2019 ; Vol. 160, No. 6. pp. 1363-1376.
@article{f88e67b0f02c47c9a41cf544adaf6a09,
title = "Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation",
abstract = "Bioactive free IGF-I is critically important for growth. The bioavailability of IGF-I is modulated by the IGF-binding proteins (IGFBPs) and their proteases, such as pregnancy-associated plasma protein-A2 (PAPP-A2). We have created a mouse model with a specific mutation in PAPPA2 identified in a human with PAPP-A2 deficiency. The human mutation was introduced to the mouse genome via a knock-in strategy, creating knock-in mice with detectable protein levels of Papp-a2 but without protease activities. We found that the Pappa2 mutation led to significant reductions in body length (10{\%}), body weight (10{\%} and 20{\%} in males and females, respectively), and relative lean mass in mice. Micro-CT analyses of Pappa2 knock-in femurs from adult mice showed inhibited periosteal bone expansion leading to more slender bones in both male and female mice. Furthermore, in the Pappa2 knock-in mice, insulin resistance correlated with decreased serum free IGF-I and increased intact IGFBP-3 concentrations. Interestingly, mice heterozygous for the knock-in mutation demonstrated a growth rate for body weight and length as well as a biochemical phenotype that was intermediate between wild-type and homozygous mice. This study models a human PAPPA2 mutation in mice. The mouse phenotype closely resembles that of the human patients, and it provides further evidence that the regulation of IGF-I bioavailability by PAPP-A2 is critical for human growth and for glucose and bone metabolism.",
author = "Masanobu Fujimoto and Melissa Andrew and Lihong Liao and Dongsheng Zhang and Gozde Yildirim and Patrick Sluss and Bhanu Kalra and Ajay Kumar and Shoshana Yakar and Vivian Hwa and Andrew Dauber",
year = "2019",
month = "6",
day = "1",
doi = "10.1210/en.2018-00755",
language = "English (US)",
volume = "160",
pages = "1363--1376",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Low IGF-I Bioavailability Impairs Growth and Glucose Metabolism in a Mouse Model of Human PAPPA2 p.Ala1033Val Mutation

AU - Fujimoto, Masanobu

AU - Andrew, Melissa

AU - Liao, Lihong

AU - Zhang, Dongsheng

AU - Yildirim, Gozde

AU - Sluss, Patrick

AU - Kalra, Bhanu

AU - Kumar, Ajay

AU - Yakar, Shoshana

AU - Hwa, Vivian

AU - Dauber, Andrew

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Bioactive free IGF-I is critically important for growth. The bioavailability of IGF-I is modulated by the IGF-binding proteins (IGFBPs) and their proteases, such as pregnancy-associated plasma protein-A2 (PAPP-A2). We have created a mouse model with a specific mutation in PAPPA2 identified in a human with PAPP-A2 deficiency. The human mutation was introduced to the mouse genome via a knock-in strategy, creating knock-in mice with detectable protein levels of Papp-a2 but without protease activities. We found that the Pappa2 mutation led to significant reductions in body length (10%), body weight (10% and 20% in males and females, respectively), and relative lean mass in mice. Micro-CT analyses of Pappa2 knock-in femurs from adult mice showed inhibited periosteal bone expansion leading to more slender bones in both male and female mice. Furthermore, in the Pappa2 knock-in mice, insulin resistance correlated with decreased serum free IGF-I and increased intact IGFBP-3 concentrations. Interestingly, mice heterozygous for the knock-in mutation demonstrated a growth rate for body weight and length as well as a biochemical phenotype that was intermediate between wild-type and homozygous mice. This study models a human PAPPA2 mutation in mice. The mouse phenotype closely resembles that of the human patients, and it provides further evidence that the regulation of IGF-I bioavailability by PAPP-A2 is critical for human growth and for glucose and bone metabolism.

AB - Bioactive free IGF-I is critically important for growth. The bioavailability of IGF-I is modulated by the IGF-binding proteins (IGFBPs) and their proteases, such as pregnancy-associated plasma protein-A2 (PAPP-A2). We have created a mouse model with a specific mutation in PAPPA2 identified in a human with PAPP-A2 deficiency. The human mutation was introduced to the mouse genome via a knock-in strategy, creating knock-in mice with detectable protein levels of Papp-a2 but without protease activities. We found that the Pappa2 mutation led to significant reductions in body length (10%), body weight (10% and 20% in males and females, respectively), and relative lean mass in mice. Micro-CT analyses of Pappa2 knock-in femurs from adult mice showed inhibited periosteal bone expansion leading to more slender bones in both male and female mice. Furthermore, in the Pappa2 knock-in mice, insulin resistance correlated with decreased serum free IGF-I and increased intact IGFBP-3 concentrations. Interestingly, mice heterozygous for the knock-in mutation demonstrated a growth rate for body weight and length as well as a biochemical phenotype that was intermediate between wild-type and homozygous mice. This study models a human PAPPA2 mutation in mice. The mouse phenotype closely resembles that of the human patients, and it provides further evidence that the regulation of IGF-I bioavailability by PAPP-A2 is critical for human growth and for glucose and bone metabolism.

UR - http://www.scopus.com/inward/record.url?scp=85065853934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065853934&partnerID=8YFLogxK

U2 - 10.1210/en.2018-00755

DO - 10.1210/en.2018-00755

M3 - Article

VL - 160

SP - 1363

EP - 1376

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -